Fund Holdings — PSP Research LLC

Total Portfolio Value:
$145.83M
Total Bought:
$145.83M
Total Sold:
$0
Net Transaction:
+$145.83M
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Ishares Tr0 3 MTH TREASURY
0-3 MTH TREASURY
0700,000+700,000$0$70.48M48.33%+$70.48M
Spdr Series TrustST STR SP BIOT
ST STR SP BIOT
0386,500+386,500$0$60.94M41.79%+$60.94M
Sera Prognostics IncCL A02,396,685+2,396,685$0$5.01M3.43%+$5.01M
Halozyme Therapeutics, Inc.(HALO)03,000+3,000$0$331.2K0.23%+$331.2K
Madrigal Pharmaceuticals, Inc.(MDGL)0600+600$0$302.4K0.21%+$302.4K
Exelixis, Inc.(EXEL)05,000+5,000$0$292.1K0.20%+$292.1K
Royalty Pharma plcCL A(RPRX)05,000+5,000$0$291.8K0.20%+$291.8K
argenx SEADR(ARGX)0300+300$0$287.7K0.20%+$287.7K
Nurix Therapeutics, Inc.(NRIX)012,000+12,000$0$284.5K0.20%+$284.5K
TG Therapeutics, Inc.(TGTX)05,000+5,000$0$278.9K0.19%+$278.9K
Tarsus Pharmaceuticals, Inc.(TARS)03,500+3,500$0$275.1K0.19%+$275.1K
Harmony Biosciences Holdings, Inc.(HRMY)07,000+7,000$0$274.8K0.19%+$274.8K
Arcutis Biotherapeutics, Inc.(ARQT)010,000+10,000$0$264.3K0.18%+$264.3K
Kiniksa Pharmaceuticals International, plcCL A(KNSA)03,500+3,500$0$261.1K0.18%+$261.1K
Supernus Pharmaceuticals06,000+6,000$0$258.2K0.18%+$258.2K
Immunome, Inc.(IMNM)012,000+12,000$0$258.1K0.18%+$258.1K
Neurocrine Biosciences, Inc.(NBIX)01,800+1,800$0$255.3K0.18%+$255.3K
Oruka Therapeutics, Inc.(ORKA)03,000+3,000$0$249.9K0.17%+$249.9K
Tango Therapeutics, Inc.(TNGX)010,000+10,000$0$249.5K0.17%+$249.5K
Definium Therapeutics, Inc.(DFTX)06,500+6,500$0$247.4K0.17%+$247.4K
Revolution Medicines, Inc.(RVMD)01,200+1,200$0$246.3K0.17%+$246.3K
Alkermes plcSHS(ALKS)06,000+6,000$0$243.1K0.17%+$243.1K
Aurinia Pharmaceuticals Inc.(AUPH)015,000+15,000$0$242.9K0.17%+$242.9K
Incyte Corporation(INCY)02,000+2,000$0$242.7K0.17%+$242.7K
Intellia Therapeutics, Inc.(NTLA)020,000+20,000$0$241.2K0.17%+$241.2K
Immunovant, Inc.(IMVT)07,000+7,000$0$236.5K0.16%+$236.5K
Stoke Therapeutics, Inc.(STOK)09,000+9,000$0$234.0K0.16%+$234.0K
Krystal Biotech, Inc.(KRYS)0692+692$0$230.1K0.16%+$230.1K
Ascendis Pharma A/S(ASND)01,000+1,000$0$227.8K0.16%+$227.8K
Syndax Pharmaceuticals Inc012,000+12,000$0$225.6K0.15%+$225.6K
Kymera Therapeutics, Inc.(KYMR)02,000+2,000$0$223.6K0.15%+$223.6K
Dianthus Therapeutics, Inc.(DNTH)02,500+2,500$0$220.1K0.15%+$220.1K
Trevi Therapeutics, Inc.(TRVI)015,000+15,000$0$214.8K0.15%+$214.8K
Mirum Pharmaceuticals, Inc.(MIRM)02,500+2,500$0$213.7K0.15%+$213.7K
Immunocore Holdings plcADS(IMCR)07,000+7,000$0$212.0K0.15%+$212.0K
Protagonist Therapeutics Inc01,500+1,500$0$211.3K0.14%+$211.3K
Edgewise Therapeutics, Inc.(EWTX)05,000+5,000$0$203.0K0.14%+$203.0K
Oric Pharmaceuticals Inc013,000+13,000$0$175.1K0.12%+$175.1K
Dyne Therapeutics, Inc.(DYN)010,000+10,000$0$161.1K0.11%+$161.1K
COMPASS Pathways plcADS(CMPS)010,000+10,000$0$124.4K0.09%+$124.4K
Ocular Therapeutix, Inc.(OCUL)015,000+15,000$0$115.0K0.08%+$115.0K
Cytomx Therapeutics Inc.039,400+39,400$0$107.2K0.07%+$107.2K
Ardelyx Inc030,000+30,000$0$102.6K0.07%+$102.6K
Olema Pharmaceuticals Inc010,000+10,000$0$86.4K0.06%+$86.4K
Page 1 of 1
PSP Research LLC — 13F Holdings — Q3 2026 | TickerTrail